Actively Recruiting
Correlation Between Vaspin Gene Polymorphism and Serum Vaspin Levels in Psoriasis Vulgaris and Its Relation to Disease Risk and Pathogenesis
Led by Aswan University · Updated on 2026-01-06
60
Participants Needed
1
Research Sites
1 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Psoriasis vulgaris is a common immune-related inflammatory skin condition that affects many people worldwide, including those in Egypt. It causes red, scaly plaques on the skin and can significantly reduce quality of life. This study explores the role of vaspin, an adipokine produced by fat tissue, and its gene variations in the development and severity of psoriasis. Researchers aim to understand how vaspin gene polymorphism relates to psoriasis risk and disease progression. The study will involve about 30 patients with psoriasis vulgaris and 30 healthy participants as a control group. Researchers will measure vaspin gene polymorphism and assess disease severity using the Psoriasis Area and Severity Index (PASI) score. This observational study does not involve medical treatments but focuses on genetic and serum analysis to find links between vaspin and psoriasis. Participants will undergo genetic testing and severity assessments over a 12-month period. The main outcome is detecting vaspin gene polymorphism and its relationship to psoriasis. The study also monitors serum vaspin levels and disease severity. Participation involves regular evaluations but no experimental therapies. The study aims to improve understanding of psoriasis pathogenesis and potential markers for the disease.
CONDITIONS
Brief Title
Correlation Between Vaspin Gene Polymorphism and Serum Vaspin Levels in Psoriasis Vulgaris
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Newly diagnosed cases or patients who have stopped psoriasis treatment for at least 6 months
- Participants of any age and gender with psoriasis vulgaris
You will not qualify if you...
- Pregnancy or breastfeeding
- Chronic diseases such as heart disease, liver disorders, chronic kidney failure, or cancer
- Presence of other inflammatory diseases like infections or autoimmune conditions
- Patients currently receiving psoriasis treatment within the last 6 months are excluded implicitly by inclusion criteria but not listed separately in source, so not included here explicitly as exclusion item only those given explicitly are listed here, following source faithfully with explicit exclusion only as per data given in eligibility_criteria field
- None other explicitly stated in source eligibility criteria beyond above exclusions, so no additional bullets included here
- Note: The source states only the above exclusion criteria explicitly
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Your Study Journey
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - Up to 12 months
Participants undergo assessments to detect vaspin gene polymorphism and measure serum vaspin levels, and psoriasis severity is evaluated using the Psoriasis Area and Severity Index (PASI) score.
1 to 2 visits depending on group assignment
Duration - Up to 12 months
Participants are observed to assess the relationship between vaspin gene polymorphism and psoriasis risk and pathogenesis over time.
Visits as needed for follow-up assessments
Trial Site Locations
Total: 1 location
1
Aswan University Hospital
Aswān, Egypt
Actively Recruiting
Research Team
O
Ola Mahmoud Samy Mohamed, MSC
M
Mahmoud Ahmed Ali, Lecturer
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
2
Similar Trials
Frequently Asked Questions
Have more questions? Get in touch with our team for quick support
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here